Leave a Message
We will call you back soon!
Your message must be between 20-3,000 characters!
Please check your E-mail!
More information facilitates better communication.
Submitted successfully!
We will call you back soon!
Leave a Message
We will call you back soon!
Your message must be between 20-3,000 characters!
Please check your E-mail!
May 20, 2021
Expanding access to cervical cancer screening is critical. About 14,000 new cases of cervical cancer are diagnosed in the U.S. each year, according to the National Institutes of Health, and more than 4,000 Americans die of the cancer every year.
Screening has proven its value and reduced the incidence of cervical cancer deaths by more than 60% since it was introduced in the 1950s. However, even before the COVID-19 pandemic, a Mayo Clinic study found that less than two-thirds of women were up to date on their cervical cancer screenings (J Womens Health 2019;28:244-9). Among those age 21–29, just over half were current.
LEARN MORE ABOUT WOMEN'S HEALTH SCREENING: http://www.alltests.com.cn/
Hangzhou AllTest Biotech CO.,LTD | |
#383, Qiaoxin Road, Xiasha Street, Qiantang Disctrict, Hangzhou, Zhejiang, P.R.China | |
86-571-56267891 | |
selina.wu@alltests.com.cn |
China Good Quality Custom Monoclonal Antibody Supplier. © 2014 - 2024 custom-monoclonalantibody.com. All Rights Reserved.